Blog

NanoPass Technologies Ltd

NanoPass Technologies to Supply MicronJet600™ Device to Immune Design for Use in ZVex-based Oncology Immunotherapy Products NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600™, its microneedle delivery device, for use with Immune

Gamida Cell

Gamida Cell plans to commence Phase III study of NiCord in 2016Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the company has reached agreements with the FDA and EMA regarding the Phase III study design outline of NiCord.  The company is moving

ReWalk Robotics Ltd.

ReWalk Robotics Launches ReWalk 6.0: the Company’s Sixth Generation Personal System for Home & Community UseThis Version of the ReWalk Personal Exoskeleton Offers Users the Fastest Walking Speed, Most Natural Gait, and the Most Precise Fit of Any ExoskeletonYOKNEAM ILIT, ISRAEL / MARLBOROUGH, MASSACHUSETTS, July 14, 2015  — ReWalk Robotics Ltd. (Nasdaq: RWLK), the leading

NanoPass Technologies Ltd.

 NanoPass Technologies Grants an Exclusive License to Circassia Pharmaceuticals, for use of its MicronJet600™ Device in Allergy Testing in the USNanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600™, its microneedle delivery device, to Circassia Pharmaceuticals plc.

ReWalk Robotics Ltd.

ReWalk Robotics Announces Expansion to India with Saimed InnovationsAgreement Will Launch First Ever Exoskeleton Rehabilitation Programs, Distribution in Northern IndiaMarlborough, MA/Kolkata, India — Exoskeleton leader ReWalk Robotics announced today a new partnership with Saimed Innovations, a leading medical technologies provider, to distribute the ReWalk exoskeleton systems in Northern India. This agreement marks a milestone for

Rewalk Robotics Ltd.

ReWalk Announces First U.S. Private Insurance Coverage for Personal System Workers’ Compensation is the First Private Insurer to Provide Payment for an Exoskeleton
Marlborough, MA — January 22, 2015 — Exoskeleton leader ReWalk Robotics announced today the first reimbursement for a personal exoskeleton system by a private U.S. insurer. This coverage comes from a health plan

Rewalk Robotics Ltd.

ReWalk Robotics announces Australian approval, distribution agreement
ReWalk Robotics has announced a collaboration with Making Strides, of Queensland, Australia. Making Strides will be the first dedicated spinal cord injury recovery center in Australia to distribute ReWalk systems in the country. ReWalk also has received approval by the Therapeutic Goods Administration (TGA) for rehabilitation and home use

Gamida Cell Ltd.

First Patient Successfully Transplanted with Cryopreserved (Frozen) NiCord® in Gamida Cell’s Ongoing Phase I/II Clinical Trial for Blood Cancers. This is the first transplantation to use a graft of ex-vivo expanded, cryopreserved, cord blood progenitor cells
Jerusalem, Israel, January 8, 2015 — Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive

Gamida Cell Ltd.

Gamida Cell’s NiCord® Receives FDA and EMA Orphan Drug Designation. NiCord® is in clinical development as a treatment for blood cancers including leukemia and lymphoma
 
Jerusalem, Israel, January 6, 2015 — Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted

Rewalk Robotics Ltd.

Spaulding Rehabilitation Hospital Launches Exoskeleton Rehabilitation Program with Rewalk Robotics.
Boston, MA – December 5, 2014 – Spaulding Rehabilitation Hospital Boston, one of the leading rehabilitation hospitals in the United States, announced the development of an exoskeleton training program utilizing the ReWalk Robotics exoskeleton systems. The Select Spaulding Clinical Team has completed basic training on the